PCSK9 and atherosclerosis: In recent years, in addition to statins, newer lipid-lowering agents acting on different mechanisms, including ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (evolocumab), have been widely used to achieve LDL-C targets in the secondary prevention of ASCVD (8).